RTW Investments LP Raises Holdings in argenx SE (NASDAQ:ARGX)

RTW Investments LP boosted its position in shares of argenx SE (NASDAQ:ARGX) by 2.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 673,497 shares of the company’s stock after acquiring an additional 19,067 shares during the period. argenx makes up approximately 6.3% of RTW Investments LP’s holdings, making the stock its 2nd largest holding. RTW Investments LP owned approximately 1.11% of argenx worth $414,201,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ARGX. GeoWealth Management LLC grew its stake in shares of argenx by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock valued at $31,000 after purchasing an additional 18 shares during the period. Whipplewood Advisors LLC bought a new stake in shares of argenx in the 4th quarter valued at approximately $37,000. Global Retirement Partners LLC grew its stake in shares of argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after purchasing an additional 48 shares during the period. FIL Ltd bought a new stake in shares of argenx in the 4th quarter valued at approximately $38,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of argenx in the 4th quarter valued at approximately $38,000. 60.32% of the stock is currently owned by institutional investors.

argenx Stock Up 5.5%

ARGX stock opened at $561.75 on Friday. The business’s fifty day moving average is $591.92 and its 200-day moving average is $612.84. The company has a market cap of $34.30 billion, a P/E ratio of -638.35 and a beta of 0.57. argenx SE has a twelve month low of $356.38 and a twelve month high of $678.21.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.32 by $0.26. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Research analysts anticipate that argenx SE will post 3.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Wedbush reiterated an “outperform” rating and issued a $715.00 price objective on shares of argenx in a research note on Friday, April 11th. Citigroup reiterated an “outperform” rating on shares of argenx in a research note on Wednesday. Wells Fargo & Company boosted their target price on argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. Oppenheimer boosted their target price on argenx from $704.00 to $708.00 and gave the stock an “outperform” rating in a report on Friday, May 9th. Finally, JMP Securities set a $699.00 target price on argenx in a report on Wednesday. One investment analyst has rated the stock with a hold rating, twenty have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $698.11.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.